Metware

Metware Biotechnology Inc. (referred to as "Metware"), established in August 2015, has its headquarters located in Wuhan National Bio-Industry Base. Additionally, the company has built an East China R&D Center in Shanghai/Jiashan, a GMP production center in Changsha, and the Wuhan Metware Medical Laboratory. It also has a North American subsidiary and is a leading metabolomics company in China. The company focuses on providing cutting-edge metabolomics technical services and innovative clinical testing product applications, committed to basic research in metabolism, molecular design breeding, disease diagnosis, drug development, and application research related to metabolomics, continuously contributing to life science research and improving human health. Metware has creatively developed a high-throughput, ultra-sensitive metabolomics technology platform centered on the "widely targeted®" (ZL201010562426.8) patented technology. It independently established an exclusive database of 2.2 million metabolites and built a multi-omics data integration analysis pipeline based on metabolomics. In recent years, relevant technical achievements have been published in international academic journals such as Cell, Nature, Nature Genetics, Nature Communications, and PNAS. The company has also been invited to give keynote presentations at conferences including the International Metabolomics Conference, the International Plant & Animal Genome Conference, the International Conference on Plant Molecular Biology, the National Rare Disease Conference, the Academic Conference on Chinese Medicine Biotechnology, and the Asia-Pacific Bioseparation and Bioanalysis Conference, leading new directions in metabolomics development. Metware has now grown into one of the fastest-growing and most productive companies in the field of metabolomics in China, establishing the largest talent team and hardware/software platforms in the industry. In 2020, the total sales of metabolomics research services ranked first in the industry, with more than 10 products under clinical mass spectrometry development. The company owns over 50 sets of high-performance LC-MS/GC-MS instruments and employs more than 400 people, nearly 40% of whom are full-time researchers. It has a top-tier metabolomics technical team in China consisting of professors who are part of the national Ten Thousand Talents Program and recipients of the National Science Fund for Distinguished Young Scholars, along with a management team from listed companies such as BGI and Novogene. The company has successively received honors such as a National High-Tech Enterprise, a National Specialized, Professional, Unique, and Innovative "Little Giant" Enterprise, a Hubei Provincial Enterprise Technology Center, a Hubei Provincial Postdoctoral Innovation Practice Base, a Hubei Provincial Service-Oriented Manufacturing Demonstration Platform, a Hubei Provincial Dual Innovation Strategic Team, a Hubei Provincial Pillar Industry Sub-sector Hidden Champion Technology Little Giant Enterprise, an Excellent Award in the Hubei Provincial High-Value Patent Competition, and inclusion in the Top 20 High-Tech and High-Growth Companies in Optics Valley. Metware's business covers: innovative metabolomics technical service CROs, early cancer screening "liquid biopsy" metabolic reagent kit development, and chronic metabolic disease prognosis reagent kit development. Its services cover scientific research institutes, hospitals, and industrial enterprises across 34 provinces, municipalities, and autonomous regions in China, serving more than 2,000 customers. Since its establishment, Metware has been dedicated to constructing a metabolomics database and developing detection methods, including independently developing a database of 2.2 million metabolites, widely targeted® metabolomics detection methods with high throughput, ultra-sensitivity, and broad coverage, and machine learning algorithms for metabolic biomarkers.